Nervous system expression of PPARγ and mutant PPARγ has profound effects on metabolic regulation and brain development

Endocrinology

Volumn 157, Issue 11, 2016, Pages 4266-4275

  Stump, Madeliene ^a,b   Guo, Deng Fu ^b   Lu, Ko Ting ^b   Mukohda, Masashi ^b   Cassell, Martin D ^b   Norris, Andrew W ^b   Rahmouni, Kamal ^a,b   Sigmund, Curt D ^a,b  

^a The University of Iowa   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; GLUCOSE; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; NESTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN MALFORMATION; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; ENERGY BALANCE; FEMALE; GENE ACTIVATION; GLUCOSE BLOOD LEVEL; HORMONE RESISTANCE; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; LIPID DIET; LIVER; MALE; METABOLIC REGULATION; MICROCEPHALY; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENE; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ADIPOGENESIS; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY COMPOSITION; BRAIN; DIET RESTRICTION; ENERGY METABOLISM; GENETICS; GLUCOSE TOLERANCE TEST; GROWTH, DEVELOPMENT AND AGING; HUMAN; INSULIN RESISTANCE; METABOLISM; MUTATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ADIPOGENESIS; ANIMALS; BODY COMPOSITION; BRAIN; DIET, HIGH-FAT; ENERGY METABOLISM; FASTING; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, TRANSGENIC; MUTATION; PPAR GAMMA; RECEPTOR, INSULIN;

EID: 84994285912     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2016-1524     Document Type: Article

References (34)

1. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet . 2005; 366:1279-1289.
2. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19: 182-187.
3. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
4. DREAM Trial Investigators, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care . 2008; 31:1007-1014.
5. Schöndorf T, Forst T, Hohberg C, et al. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab . 2007;9:132-133.
6. HomePD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet . 2009;373:2125-2135.
7. Sarruf DA, Yu F, Nguyen HT, et al. Expression of peroxisome proliferator-Activated receptor-γ in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology. 2009; 150:707-712.
8. Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011;17:618-622.
9. Ryan KK, Li B, Grayson BE, Matter EK, WoodsSC, Seeley RJ. Arole for central nervous system PPAR-γ in the regulation of energy balance. Nat Med. 2011;17:623-626.
10. Diano S, Liu ZW, Jeong JK, et al. Peroxisome proliferation-Associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med . 2011;17:1121-1127.
11. Long L, Toda C, Jeong JK, Horvath TL, Diano S. PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding. J Clin Invest. 2014;124:4017-4027.
12. Stump M, Guo DF, Lu KT, et al. Effect of selective expression of dominant negative PPARγ in proopiomelanocortin neurons on the control of energy balance. Physiol Genomics . 2016;48:491-501.
13. Ketsawatsomkron P, Keen HL, Davis DR, et al. Protective role for tissue inhibitor of metalloproteinase-4, a novel peroxisome proliferator-Activated receptor-γ target gene, in smooth muscle in deoxycorticosterone acetate-salt hypertension. Hypertension. 2016;67: 214-222.
14. Tronche F, Kellendonk C, Kretz O, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99-103.
15. Burnett CM, Grobe JL. Direct calorimetry identifies deficiencies in respirometry for the determination of resting metabolic rate in C57Bl/6 and FVB mice.AmJ Physiol Endocrinol Metab . 2013;305: E916-E924.
16. Morgan DA, Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice. J Hypertens. 2010;28: 1913-1919.
17. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
18. Barak Y, NelsonMC, OngES, et al.PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-595.
19. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-Activated receptor-γ. Diabetes . 2003;52: 910-917.
20. Li G, Leff T. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-Activated receptor-γ mutations associated with diabetes. Mol Endocrinol . 2007;21:857-864.
21. Keen HL, Halabi CM, Beyer AM, et al. Bioinformatic analysis of gene sets regulated by ligand-Activated and dominant-negative peroxisome proliferator-Activated receptor γ in mouse aorta. Arterioscler Thromb Vasc Biol . 2010;30:518-525.
22. Keen HL, Ryan MJ, Beyer A, et al. Gene expression profiling of potential PPARγ target genes in mouse aorta. Physiol Genomics. 2004;18:33-42.
23. Galichet C, Lovell-Badge R, Rizzoti K. Nestin-Cre mice are affected by hypopituitarism, which is not due to significant activity of the transgene in the pituitary gland. PLoS One. 2010;5:e11443.
24. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001;86:5176-5183.
25. Jackson RL, Kelly HG. Growth of children with diabetes mellitus in relationship to level of control of the disease. J Pediatr. 1946;29: 316-328.
26. Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res . 1985; 19:879-886.
27. Hoskins PJ, Leslie RD, Pyke DA. Height at diagnosis of diabetes in children: a study in identical twins. Br Med J (Clin Res Ed). 1985; 290:278-280.
28. Rudolf MC, Sherwin RS, Markowitz R, et al. Effect of intensive insulin treatment on linear growth in the young diabetic patient. J Pediatr. 1982;101:333-339.
29. Winter RJ, Phillips LS, Green OC, Traisman HS. Somatomedin activity in the Mauriac syndrome. J Pediatr. 1980;97:598-600.
30. Guevara-Aguirre J, Rosenbloom AL, Vaccarello MA, et al. Growth hormone receptor deficiency (Laron syndrome): clinical and genetic characteristics. Acta Paediatr Scand Suppl. 1991;377:96-103.
31. Cui D, Li F, Li Q, et al. Generation of a miniature pig disease model for human Laron syndrome. Sci Rep. 2015;5:15603.
32. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA . 1997;94:13215-13220.
33. Marino JS, Xu Y, Hill JW. Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol Metab. 2011;22:275-285.
34. Vogt MC, Paeger L, Hess S, et al. Neonatal insulin action impairs hypothalamic neurocircuit formation in response to maternal highfat feeding. Cell. 2014;156:495-509